A phase IIIB, partially blind, randomized study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ measles-mumps-rubella-varicella vaccine (MeMuRu-OKA) given to healthy children during the second year of life following a 4-week and a 12-month interval between two doses - MMRV-042 & MMRV-045

GlaxoSmithKline Biologicals0 个研究点目标入组 540 人开始时间: 2005年6月1日最近更新: 2012年3月19日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方: GlaxoSmithKline Biologicals
入组人数: 540

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•All subjects must satisfy the following criteria at study entry:
•? Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits) should be enrolled in the study.
•? A male or female subject between 11-13 months of age (i.e. from 11-month birthday until the day before the 14-month birthday) at the time of the first vaccination.
•Note: Subjects to be enrolled in Germany should receive two doses of the vaccine during the second year of life according to the local recommendation. To comply with this recommendation, the age of subjects at the time of the first vaccination in Germany is suggested to be from 11-month to 12.5-month of age.
•? Written informed consent obtained from the parent or guardian of the subject (or from both parents as required in The Netherlands).
•? Free of obvious health problems as established by medical history and clinical examination before entering into the study.
•Are the trial subjects under 18? yes
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

排除标准

•The following criteria should be checked at the time of study entry. If any apply, the subject must not be included in the study:
•- Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
•- Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. (For corticosteroids, this will mean prednisone, or equivalent, = 0.5 mg/kg/day. Inhaled and topical steroids are allowed.)
•- Planned administration/ administration of a vaccine not foreseen by the study protocol from 30 days prior to each vaccination until 42-56 days after each vaccination.
•N. meningitidis type C conjugate vaccine is allowed to be given up to seven days - Previous vaccination against against measles, mumps, rubella and/or varicella.
•- History of measles, mumps, rubella and/or varicella/zoster diseases.
•- Known exposure to measles, mumps, rubella and/or varicella/zoster within 30 days prior to the start of the present trial.
•- Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.
•- A family history of congenital or hereditary immunodeficiency.
•- History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
•- Major congenital defects or serious chronic illness.
•- History of any neurologic disorders or seizures.
•- Residence in the same household as the following persons:
•? New-born infants (0-4 weeks of age).
•? Pregnant mother/women with a negative history of chickenpox disease and without recorded vaccination against chickenpox.
•? Persons with known immunodeficiency.
•- Acute disease at the time of enrolment. (Acute disease is defined as the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with a minor illness such as diarrhoea, mild upper respiratory infection with or without low-grade febrile illness, i.e., axillary temperature <37.5°C / rectal temperature <38°C.
•- Rectal temperature =38.0ºC or axillary temperature =37.5ºC at the time of vaccination.
•- Administration of immunoglobulins and/or any blood products during the six months before entering the study or planned administration during the study period.

研究者

发起方

GlaxoSmithKline Biologicals

相似试验

进行中（未招募）

不适用

A phase IIIB, partially blind, randomized study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ measles-mumps-rubella-varicella vaccine (MeMuRu-OKA) given to healthy children during the second year of life following a 4-week and a 12-month interval between two doses - MMRV-042 & MMRV-045Active immunization of healthy children during their second year of life against measles, mumps, rubella and varicella diseases.

EUCTR2004-004371-11-BEGlaxoSmithKline Biologicals540

进行中（未招募）

不适用

EUCTR2011-004638-32-Outside-EU/EEAGlaxoSmithKline Biologicals4,000

进行中（未招募）

不适用

EUCTR2011-003672-36-EEGlaxoSmithKline Biologicals1,000

进行中（未招募）

不适用

Immunogenicity and safety study of GSK Biologicals´ combined measles-mumps-rubella vaccine in subjects seven years of age and older (209762).

EUCTR2011-003672-36-SKGlaxoSmithKline Biologicals S.A.1,000

进行中（未招募）

不适用

A phase III, observer-blind, randomized, study in adults aged between 18 and 60 years to assess the immunological equivalence of the Quebec-manufactured A/California/7/2009 (H1N1)v-like antigen adjuvanted with AS03A as compared to the Dresden-manufactured A/California/7/2009 (H1N1)v-like antigen adjuvanted with AS03A. - FLU D-PAN H1N1-017Immunization against A/California/7/2009 (H1N1)v-like influenza in male and female subjects aged 18 to 60 years.

EUCTR2009-014419-11-DEGlaxoSmithKline Biologicals320